B.P. Pharma
Egypt-based pharmaceutical company (founded 1988) focused on introducing, registering, importing, distributing and marketing pharmaceutical products with emphasis on neurology and related therapeutic areas. Operates a portfolio of oral, injectable and specialty formulations, pursues regional market expansion, and states plans to establish an in-house R&D center.
Industries
Nr. of Employees
medium (51-250)
B.P. Pharma
Plot 17 & 18, 6th Industrial Zone, 6 October City, Giza, Egypt
Products
Amantadine sulfate — intravenous solution (200 mg / 500 mg)
IV solution indicated for Parkinson's disease symptom management and described antiviral activity against some influenza A strains.
Donepezil + Memantine — oral capsules
Oral combination therapy for moderate to severe Alzheimer's disease targeting memory and cognition.
Zileuton — 600 mg film-coated / extended-release tablets
Oral leukotriene synthesis inhibitor indicated for chronic asthma prophylaxis.
Carbamazepine — sustained-release and film-coated tablets
Anticonvulsant formulations for seizure control and neuropathic pain.
Citicoline — injectable solution and oral solution
Parenteral and oral formulations for disorders of consciousness, stroke rehabilitation and brain injury recovery support.
Paroxetine — orally disintegrating tablet (20 mg ODT)
Selective serotonin reuptake inhibitor formulation for depression, anxiety disorders and related indications in an ODT format.
Amantadine sulfate — intravenous solution (200 mg / 500 mg)
IV solution indicated for Parkinson's disease symptom management and described antiviral activity against some influenza A strains.
Donepezil + Memantine — oral capsules
Oral combination therapy for moderate to severe Alzheimer's disease targeting memory and cognition.
Zileuton — 600 mg film-coated / extended-release tablets
Oral leukotriene synthesis inhibitor indicated for chronic asthma prophylaxis.
Carbamazepine — sustained-release and film-coated tablets
Anticonvulsant formulations for seizure control and neuropathic pain.
Citicoline — injectable solution and oral solution
Parenteral and oral formulations for disorders of consciousness, stroke rehabilitation and brain injury recovery support.
Paroxetine — orally disintegrating tablet (20 mg ODT)
Selective serotonin reuptake inhibitor formulation for depression, anxiety disorders and related indications in an ODT format.
Services
Regulatory submissions and market entry support for pharmaceutical products.
Regulatory submissions and market entry support for pharmaceutical products.
Expertise Areas
- Neurology therapeutics
- Pharmaceutical product registration and market access
- Pharmaceutical commercialization and marketing
- Formulation and dosage-form development
Key Technologies
- Sustained-release / extended-release formulations
- Oral disintegrating tablet formulations
- Injectable solutions and ampoule formulations
- Nasal spray formulations
News & Updates
The company reports positive negotiations with potential new business partners interested in cooperation.
Announcement referencing a milestone for the company in February 2019.
Reference to inclusion of a neurorehabilitation medication in German Neurorehab Guidelines (DGNR) reported July 2020.
The company reports positive negotiations with potential new business partners interested in cooperation.
Announcement referencing a milestone for the company in February 2019.
Reference to inclusion of a neurorehabilitation medication in German Neurorehab Guidelines (DGNR) reported July 2020.